Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. 8-K filed Aug 27, 2025

Period ended Aug 27, 2025 · Filed · accepted 4:21 PM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits